Cheng B - Search Results

1

Dose Individualization for Phase I Cancer Trials With Broadened Eligibility.

Silva RB, Cheng B, Carvajal RD, Lee SM. Silva RB, et al. Among authors: cheng b. Stat Med. 2024 Dec 20;43(29):5534-5547. doi: 10.1002/sim.10264. Epub 2024 Oct 31. Stat Med. 2024. PMID: 39479896

2

Incorporating patient-reported outcomes in dose-finding clinical trials.

Lee SM, Lu X, Cheng B. Lee SM, et al. Among authors: cheng b. Stat Med. 2020 Feb 10;39(3):310-325. doi: 10.1002/sim.8402. Epub 2019 Dec 3. Stat Med. 2020. PMID: 31797421 Free PMC article.

3

Seamless phase I/II design for novel anticancer agents with competing disease progression.

Biard L, Lee SM, Cheng B. Biard L, et al. Among authors: cheng b. Stat Med. 2021 Sep 20;40(21):4568-4581. doi: 10.1002/sim.9080. Epub 2021 Jul 2. Stat Med. 2021. PMID: 34213022 Free PMC article.

4

A simulation study of approaches for handling disease progression in dose-finding clinical trials.

Biard L, Cheng B, Manji GA, Lee SM. Biard L, et al. Among authors: cheng b. J Biopharm Stat. 2021 Mar;31(2):156-167. doi: 10.1080/10543406.2020.1814796. Epub 2020 Sep 15. J Biopharm Stat. 2021. PMID: 32931360

5

Continual reassessment method with multiple toxicity constraints.

Lee SM, Cheng B, Cheung YK. Lee SM, et al. Among authors: cheng b. Biostatistics. 2011 Apr;12(2):386-98. doi: 10.1093/biostatistics/kxq062. Epub 2010 Sep 28. Biostatistics. 2011. PMID: 20876664 Free PMC article.

6

Assessing departure from dose linearity under a repeated measures incomplete block design.

Cheng B, Chow SC. Cheng B, et al. Pharm Stat. 2011 Jul-Aug;10(4):357-62. doi: 10.1002/pst.474. Epub 2010 Nov 22. Pharm Stat. 2011. PMID: 21104786

7

Adding dose modifications into Phase II and Phase II/III seamless trials.

Spivack J, Cheng B, Levin B. Spivack J, et al. Among authors: cheng b. Stat Methods Med Res. 2020 May;29(5):1315-1324. doi: 10.1177/0962280219859387. Epub 2019 Jul 3. Stat Methods Med Res. 2020. PMID: 31267845

8

On the assessment of dose proportionality: a comparison of two slope approaches.

Cheng B, Chow SC, Su WL. Cheng B, et al. J Biopharm Stat. 2006 May;16(3):385-92. doi: 10.1080/10543400600629906. J Biopharm Stat. 2006. PMID: 16724492

9

ZERO-INFLATED QUANTILE RANK-SCORE BASED TEST (ZIQRANK) WITH APPLICATION TO SCRNA-SEQ DIFFERENTIAL GENE EXPRESSION ANALYSIS.

Ling W, Zhang W, Cheng B, Wei Y. Ling W, et al. Among authors: cheng b. Ann Appl Stat. 2021 Dec;15(4):1673-1696. doi: 10.1214/21-aoas1442. Epub 2021 Dec 21. Ann Appl Stat. 2021. PMID: 35116085 Free PMC article.

10

On flexibility of adaptive designs and criteria for choosing a good one--a discussion of FDA draft guidance.

Cheng B, Chow SC. Cheng B, et al. J Biopharm Stat. 2010 Nov;20(6):1171-7. doi: 10.1080/10543406.2010.514460. J Biopharm Stat. 2010. PMID: 21058113

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,241 results

Search Page

Filters